MAPT and amyloidosis: For AD, the amyloid/tau/neurodegeneration or “AT(N)” criteria, using CSF and/or PET imaging, has been instrumental in accurately detecting both the presence of Aβ and tau pathology, and to stage patients along the AD continuum.9